688505 复旦张江
已收盘 03-06 15:00:01
资讯
新帖
简况
港股异动 | 复旦张江(01349)跌超4% 去年同比盈转亏约1.57亿元
智通财经 · 03-02
港股异动 | 复旦张江(01349)跌超4% 去年同比盈转亏约1.57亿元
每周股票复盘:复旦张江(688505)净利亏损1.57亿
证券之星 · 03-01
每周股票复盘:复旦张江(688505)净利亏损1.57亿
复旦张江发布2025年度业绩快报,亏损1.574亿元
证券之星 · 02-27
复旦张江发布2025年度业绩快报,亏损1.574亿元
复旦张江:更换持续督导保荐代表人
证券日报 · 02-09
复旦张江:更换持续督导保荐代表人
复旦张江公布国际专利申请:“一种蒽环类化合物及其制备方法、中间体和应用”
证券之星 · 02-08
复旦张江公布国际专利申请:“一种蒽环类化合物及其制备方法、中间体和应用”
港股异动 | 复旦张江(01349)盘中跌4% 预计2025年由盈转亏最多1.8亿元
智通财经 · 02-02
港股异动 | 复旦张江(01349)盘中跌4% 预计2025年由盈转亏最多1.8亿元
复旦张江(01349)发盈警 预计2025年度归母净亏损约1.2亿至1.8亿元
智通财经 · 01-30
复旦张江(01349)发盈警 预计2025年度归母净亏损约1.2亿至1.8亿元
复旦张江:研发投入占营收比重提升,预期业绩向好
美股速递 · 01-30
复旦张江:研发投入占营收比重提升,预期业绩向好
复旦张江预计全年净亏损1.2亿至1.8亿元
美股速递 · 01-30
复旦张江预计全年净亏损1.2亿至1.8亿元
复旦张江(688505)披露盐酸氨酮戊酸口服溶液用粉末获上市申请受理通知书,1月29日股价下跌0.68%
证券之星 · 01-29
复旦张江(688505)披露盐酸氨酮戊酸口服溶液用粉末获上市申请受理通知书,1月29日股价下跌0.68%
复旦张江最新公告:盐酸氨酮戊酸口服溶液用粉末用于脑胶质瘤手术可视化获得药物上市申请受理通知书
证券之星 · 01-29
复旦张江最新公告:盐酸氨酮戊酸口服溶液用粉末用于脑胶质瘤手术可视化获得药物上市申请受理通知书
每周股票复盘:复旦张江(688505)股东减持1036万股占总股本1.00%
证券之星 · 01-18
每周股票复盘:复旦张江(688505)股东减持1036万股占总股本1.00%
股市必读:1月13日复旦张江发布公告,股东减持794.88万股
证券之星 · 01-14
股市必读:1月13日复旦张江发布公告,股东减持794.88万股
复旦张江:杨宗孟已减持1.00%股份
南方财经网 · 01-13
复旦张江:杨宗孟已减持1.00%股份
复旦张江(01349):认购招商银行结构性存款产品
智通财经 · 01-07
复旦张江(01349):认购招商银行结构性存款产品
复旦张江认购平安银行2.7亿元结构性存款产品
美股速递 · 01-07
复旦张江认购平安银行2.7亿元结构性存款产品
复旦张江与中国银行签署结构性存款产品协议
美股速递 · 01-06
复旦张江与中国银行签署结构性存款产品协议
复旦张江:持股5%以上股东杨宗孟减持公司股份至5.94%
每日经济新闻 · 01-05
复旦张江:持股5%以上股东杨宗孟减持公司股份至5.94%
复旦张江(01349)向浦发银行认购总金额为2.1亿元的结构性存款产品
智通财经 · 01-04
复旦张江(01349)向浦发银行认购总金额为2.1亿元的结构性存款产品
每周股票复盘:复旦张江(688505)肺癌术中显影获临床受理
证券之星 · 2025-12-28
每周股票复盘:复旦张江(688505)肺癌术中显影获临床受理
公司概况
公司名称:
上海复旦张江生物医药股份有限公司
所属行业:
医药制造业
上市日期:
2020-06-19
主营业务:
上海复旦张江生物医药股份有限公司的主营业务是生物医药的创新研究开发、生产制造和市场营销。公司的主要产品是皮肤科产品、抗肿瘤产品。
发行价格:
8.95
{"stockData":{"symbol":"688505","market":"SH","secType":"STK","nameCN":"复旦张江","latestPrice":8.19,"timestamp":1772780401000,"preClose":8.05,"halted":0,"volume":3154963,"delay":0,"changeRate":0.0174,"floatShares":711000000,"shares":1036999999,"eps":-0.0605,"marketStatus":"已收盘","change":0.14,"latestTime":"03-06 15:00:01","open":8.03,"high":8.22,"low":8.03,"amount":25761000,"amplitude":0.0236,"askPrice":8.2,"askSize":272,"bidPrice":8.19,"bidSize":1228,"shortable":0,"etf":0,"ttmEps":-0.0605,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773019800000},"marketStatusCode":5,"adr":0,"adjPreClose":8.05,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772760600000,1772767800000],[1772773200000,1772780400000]],"highLimit":8.86,"lowLimit":7.25,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1036572100,"isCdr":false,"pbRate":3.76,"roa":"--","roe":"--","epsLYR":0.04,"committee":0.534417,"marketValue":8490000000,"turnoverRate":0.0044,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-03-09。","afterMarket":{"amount":0,"volume":0,"close":8.19,"buyVolume":0,"sellVolume":0,"time":1772782437558,"indexStatus":"已收盘 03-06 15:30:00","preClose":8.05},"hkstockBrief":{"symbol":"01349","market":"HK","secType":"STK","nameCN":"复旦张江","latestPrice":3.08,"timestamp":1772784497426,"preClose":3.03,"halted":0,"volume":987000,"delay":0,"premium":"-66.82"},"floatMarketCap":5820000000},"requestUrl":"/m/hq/s/688505/wiki","defaultTab":"wiki","newsList":[{"id":"2616858743","title":"港股异动 | 复旦张江(01349)跌超4% 去年同比盈转亏约1.57亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616858743","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616858743?lang=zh_cn&edition=full","pubTime":"2026-03-02 15:19","pubTimestamp":1772435941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,复旦张江(01349)跌超4%,截至发稿,跌4.15%,报3港元,成交额752.2万港元。消息面上,2月27日,复旦张江公布2025年业绩快报,营业收入约6.86亿元,同比减少3.33%;归属于上市公司股东的净亏损约1.57亿元,同比盈转亏。报告期内,集团生产经营正常,主要上市销售药品种类未发生变化。由于盐酸多柔比星脂质体注射液被纳入国家集采目录,公司产品里葆多®未获中选,依据相关集采规则以及市场竞争格局的改变,公司于报告期内相应调整里葆多®销售策略,包括但不限于自2025年5月1日起梯度下调其市场零售价格,导致其利润率相应下降。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688505","BK4585","BK4588","BK1191","VXUS","BK0239","01349","VT"],"gpt_icon":0},{"id":"2616454728","title":"每周股票复盘:复旦张江(688505)净利亏损1.57亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2616454728","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616454728?lang=zh_cn&edition=full","pubTime":"2026-03-01 03:00","pubTimestamp":1772305238,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,复旦张江报收于8.68元,较上周的8.62元上涨0.7%。本周,复旦张江2月25日盘中最高价报8.76元。本周关注点来自业绩披露要点:复旦张江2025年归属净利润亏损1.574亿元,同比减少496.23%。公司公告汇总复旦张江2025年度业绩快报公告上海复旦张江生物医药股份有限公司发布2025年度业绩快报,营业总收入685,797,316元,同比下降3.33%;营业利润-155,402,230元,同比大幅下滑6,591.74%;归属于母公司所有者的净利润为-157,439,498元,同比下降496.23%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","01349","688505","BK0239"],"gpt_icon":0},{"id":"2614949839","title":"复旦张江发布2025年度业绩快报,亏损1.574亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614949839","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614949839?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:51","pubTimestamp":1772185888,"startTime":"0","endTime":"0","summary":"证券之星消息,复旦张江近日即将发布2025年年报,根据2月27日发布的业绩快报,归属净利润亏损1.574亿元,同比减少496.23%。报告期内本集团研发投入约人民币 3.58 亿元。销售策略,导致该产品的利润贡献与上年同期相比减少约人民币 1 亿元。同时,本集团积极推动研发项目进展,研发费用较上年同期增加约人民币 4,400 万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700030187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","01349","688505"],"gpt_icon":0},{"id":"2610763721","title":"复旦张江:更换持续督导保荐代表人","url":"https://stock-news.laohu8.com/highlight/detail?id=2610763721","media":"证券日报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610763721?lang=zh_cn&edition=full","pubTime":"2026-02-09 20:08","pubTimestamp":1770638933,"startTime":"0","endTime":"0","summary":"证券日报网讯2月9日,复旦张江发布公告称,公司首次公开发行股票并在科创板上市项目(以下简称“本项目”)的保荐机构为国泰海通证券股份有限公司(以下简称“国泰海通”),本项目法定持续督导期间为2020年6月19日至2023年12月31日,郑干国先生、陈恒瑞先生为本项目持续督导期间的保荐代表人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602093645633736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","688505","BK0239","01349"],"gpt_icon":0},{"id":"2609521885","title":"复旦张江公布国际专利申请:“一种蒽环类化合物及其制备方法、中间体和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2609521885","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609521885?lang=zh_cn&edition=full","pubTime":"2026-02-08 05:39","pubTimestamp":1770500362,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示复旦张江(688505)公布了一项国际专利申请,专利名为“一种蒽环类化合物及其制备方法、中间体和应用”,专利申请号为PCT/CN2025/112113,国际公布日为2026年2月5日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来复旦张江已公布的国际专利申请1个。结合公司2025年中报财务数据,2025上半年公司在研发方面投入了1.78亿元,同比增15.13%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","01349","BK1191","688505"],"gpt_icon":0},{"id":"2608360038","title":"港股异动 | 复旦张江(01349)盘中跌4% 预计2025年由盈转亏最多1.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360038","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608360038?lang=zh_cn&edition=full","pubTime":"2026-02-02 11:11","pubTimestamp":1770001874,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,复旦张江盘中跌4%,截至发稿,跌3.69%,报3.13港元,成交额371.59万港元。消息面上,复旦张江公布,集团预计截至2025年12月31日止年度将取得未经审核的归属于母公司所有者的净亏损约为人民币1.2亿元至1.8亿元,2024年同期净利润为人民币3973.39万元;未经审核的归属于母公司所有者的扣除非经常性损益的净亏损约为人民币1.4亿元至2亿元,2024年扣除非经常性损益的净利润为人民币514.52万元。期内研发投入约3.5亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","688505","BK4585","01349","BK1191","BK4588","BK0239"],"gpt_icon":0},{"id":"2607014795","title":"复旦张江(01349)发盈警 预计2025年度归母净亏损约1.2亿至1.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607014795","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607014795?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:19","pubTimestamp":1769771965,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复旦张江 发布公告,集团预计截至2025年12月31日止年度将取得未经审核的归属于母公司所有者的净亏损约为人民币1.2亿元至1.8亿元;未经审核的归属于母公司所有者的扣除非经常性损益的净亏损约为人民币1.4亿元至2亿元。报告期内集团研发投入约人民币3.5亿元。与去年同期相比,该产品对集团的利润贡献同比减少约人民币1亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","01349","BK1191","688505"],"gpt_icon":0},{"id":"1134191638","title":"复旦张江:研发投入占营收比重提升,预期业绩向好","url":"https://stock-news.laohu8.com/highlight/detail?id=1134191638","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134191638?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:13","pubTimestamp":1769771580,"startTime":"0","endTime":"0","summary":"随着研发投入在集团整体营收中所占比例的持续攀升,上海复旦张江生物医药股份有限公司(以下简称“复旦张江”)的预期业绩表现有望得到积极提振。公司不断加大在创新药物研发领域的投入力度,这一战略举措预计将为其未来增长奠定坚实基础,并进一步增强市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688505","BK0239"],"gpt_icon":0},{"id":"1179316637","title":"复旦张江预计全年净亏损1.2亿至1.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179316637","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179316637?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:08","pubTimestamp":1769771290,"startTime":"0","endTime":"0","summary":"复旦张江(688505)发布业绩预告称,经初步测算,公司全年归属于上市公司股东的净利润将出现亏损,预计亏损金额在1.2亿元至1.8亿元之间。本次披露数据尚未经审计,最终财务数据以公司正式披露的年度报告为准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688505"],"gpt_icon":0},{"id":"2607039496","title":"复旦张江(688505)披露盐酸氨酮戊酸口服溶液用粉末获上市申请受理通知书,1月29日股价下跌0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607039496","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607039496?lang=zh_cn&edition=full","pubTime":"2026-01-29 23:22","pubTimestamp":1769700133,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘,复旦张江报收于8.74元,较前一交易日下跌0.68%,最新总市值为90.6亿元。该股当日开盘8.81元,最高8.86元,最低8.71元,成交额达4885.71万元,换手率为0.78%。近日,上海复旦张江生物医药股份有限公司全资子公司泰州复旦张江药业有限公司收到国家药品监督管理局签发的《受理通知书》,盐酸氨酮戊酸口服溶液用粉末用于成人恶性高级别脑胶质瘤患者术中恶性组织可视化的药物上市申请已获受理。该事项对公司近期业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900044494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","01349","BK0239","688505"],"gpt_icon":0},{"id":"2607700883","title":"复旦张江最新公告:盐酸氨酮戊酸口服溶液用粉末用于脑胶质瘤手术可视化获得药物上市申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2607700883","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607700883?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:41","pubTimestamp":1769679682,"startTime":"0","endTime":"0","summary":"复旦张江(688505.SH)公告称,公司全资子公司泰州复旦张江药业有限公司收到国家药品监督管理局核准签发的《受理通知书》,盐酸氨酮戊酸口服溶液用粉末用于成人恶性高级别脑胶质瘤患者术中恶性组织可视化的药物上市申请获得受理。该药物未来如能获批上市,将进一步丰富公司的产品线,增强公司整体竞争力。但药品上市注册批件取得的时间和结果具有不确定性,该药物上市申请获得受理对公司近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900030099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","01349","688505"],"gpt_icon":0},{"id":"2604925597","title":"每周股票复盘:复旦张江(688505)股东减持1036万股占总股本1.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604925597","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604925597?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:49","pubTimestamp":1768679346,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,复旦张江报收于8.65元,较上周的8.84元下跌2.15%。本周,复旦张江1月12日盘中最高价报9.24元。本周关注点股本股东变化:股东杨宗孟减持10,365,721股,占总股本1.00%。股本股东变化股东增减持1月13日复旦张江发布公告,股东杨宗孟于2026年1月6日至2026年1月12日间合计减持794.88万股,占公司目前总股本的0.7668%。此前,杨宗孟持有公司64,009,773股,占总股本6.18%,减持后持股降至53,644,052股,占总股本5.18%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","01349","688505","BK1191"],"gpt_icon":0},{"id":"2603632904","title":"股市必读:1月13日复旦张江发布公告,股东减持794.88万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603632904","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603632904?lang=zh_cn&edition=full","pubTime":"2026-01-14 02:54","pubTimestamp":1768330451,"startTime":"0","endTime":"0","summary":"来自股本股东变化:股东杨宗孟在1月6日至1月12日期间合计减持794.88万股,占总股本的0.7668%。股本股东变化股东增减持1月13日复旦张江发布公告《复旦张江:复旦张江关于持股5%以上股东减持股份结果公告》,其股东杨宗孟于2026年1月6日至2026年1月12日间合计减持794.88万股,占公司目前总股本的0.7668%,变动期间该股股价上涨3.21%,截止1月12日收盘报9.0元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400001408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688505","BK1191","BK0239","01349"],"gpt_icon":0},{"id":"2603046805","title":"复旦张江:杨宗孟已减持1.00%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603046805","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603046805?lang=zh_cn&edition=full","pubTime":"2026-01-13 17:08","pubTimestamp":1768295295,"startTime":"0","endTime":"0","summary":"21智讯1月13日电,复旦张江公告,公司股东杨宗孟先生于2025年11月26日至2026年1月12日期间通过集中竞价交易方式累计减持公司股份10,365,721股,占公司总股本的1.00%。本次减持计划已实施完毕,减持价格区间为8.64至9.22元/股,减持总金额为9108.30万元。减持后,杨宗孟先生持有公司股份53,644,052股,持股比例由6.18%下降至5.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617421034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK0239","688505","01349"],"gpt_icon":0},{"id":"2601783875","title":"复旦张江(01349):认购招商银行结构性存款产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2601783875","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601783875?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:12","pubTimestamp":1767777166,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复旦张江(01349)发布公告,近日,本公司与招商银行订立招商银行结构性存款产品协议 I,本公司的全资附属公司泰州复旦张江与招商银行订立招商银行结构性存款产品协议 II,据此,本集团同意以日常营运产生的自有闲置资金向招商银行认购总金额为人民币1.10亿元的结构性存款产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0327786744.USD","LU1008478684.HKD","LU1048596156.SGD","LU1152091168.USD","688505","LU1993786604.SGD","03143","BK0012","LU0821914370.USD","SG9999002828.SGD","LU2226246903.HKD","LU0348814723.USD","LU1997244956.HKD","IE0008368742.USD","LU1813983027.USD","LU0918141705.HKD","01349","IE00BF5LJ272.USD","LU2778985437.USD","LU0593848301.USD","IE00BZ08YT58.USD","LU1152091754.HKD","IE00BGHQDM52.EUR","SG9999002463.SGD","LU0348735423.USD","LU0463099449.HKD","LU0516422952.EUR","LU0244354667.USD","LU2242644610.SGD","LU0488056044.USD","LU0047713382.USD","LU0348788117.USD","LU0880133367.SGD","LU1242518931.SGD","LU0384037296.USD","600036","BK1191","SG9999000459.SGD","LU1820825898.SGD","LU1328277881.USD","LU2213484517.USD","LU1808992512.USD","LU0516422366.SGD","LU2476274308.USD","03968","LU1961090484.USD","LU0173614495.USD","LU1282649810.SGD","LU0634319403.HKD"],"gpt_icon":0},{"id":"1131080784","title":"复旦张江认购平安银行2.7亿元结构性存款产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1131080784","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131080784?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:07","pubTimestamp":1767776868,"startTime":"0","endTime":"0","summary":"复旦张江(股票代码:688505)近日公告,公司已使用部分闲置自有资金,向平安银行认购了一款结构性存款产品,认购总额为人民币2.7亿元。此举旨在提高公司资金使用效率,在确保资金流动性和安全性的前提下,增加公司现金资产的收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688505"],"gpt_icon":0},{"id":"1156431567","title":"复旦张江与中国银行签署结构性存款产品协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1156431567","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156431567?lang=zh_cn&edition=full","pubTime":"2026-01-06 18:07","pubTimestamp":1767694031,"startTime":"0","endTime":"0","summary":"复旦张江(股票代码:688505)已正式与中国银行达成一项结构性存款产品协议。该协议的签署旨在优化公司资金管理,提升闲置资金的使用效率,在保障资金安全的前提下获取更稳健的财务收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688505","BK0239"],"gpt_icon":0},{"id":"2601884418","title":"复旦张江:持股5%以上股东杨宗孟减持公司股份至5.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884418","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601884418?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:51","pubTimestamp":1767610297,"startTime":"0","endTime":"0","summary":"每经AI快讯,1月5日,复旦张江公告称,2025年11月26日至2026年1月5日,股东杨宗孟通过集中竞价交易累计减持241.6908万股。其持股由6400.9773万股降至6159.2865万股,占总股本比例由6.18%降至5.94%。此次权益变动触及1%整数倍,且该减持为履行此前计划,截至公告披露日,减持计划尚未实施完毕。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601053608965891.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601053608965891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01349","688505","BK0239","BK1191"],"gpt_icon":0},{"id":"2600479100","title":"复旦张江(01349)向浦发银行认购总金额为2.1亿元的结构性存款产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2600479100","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600479100?lang=zh_cn&edition=full","pubTime":"2026-01-04 18:41","pubTimestamp":1767523288,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复旦张江(01349)发布公告,近日,公司与浦发银行订立浦发银行结构性存款产品协议,同意以日常营运产生的自有闲置资金向浦发银行认购总金额为人民币2.1亿元的结构性存款产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1808992512.USD","BK0015","BK0028","BK0187","BK1191","BK0183","BK0278","SGXZ49509284.SGD","SGXZ81163826.USD","BK0239","01349","LU1934453819.USD","LU1979443071.USD","600000","BK0086","LU0469268626.HKD","BK0012","BK0188","688505","BK0201"],"gpt_icon":0},{"id":"2594479032","title":"每周股票复盘:复旦张江(688505)肺癌术中显影获临床受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2594479032","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594479032?lang=zh_cn&edition=full","pubTime":"2025-12-28 05:17","pubTimestamp":1766870230,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,复旦张江报收于8.32元,较上周的8.41元下跌1.07%。本周关注点公司公告汇总:注射用FZ-P001钠用于肺癌术中显影获II期临床试验受理。目前该药物已完成卵巢癌适应症I期临床试验,新适应症II期临床试验申请已获受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","01349","688505","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772819340319,"stockEarnings":[{"period":"1week","weight":-0.0565},{"period":"1month","weight":-0.0455},{"period":"3month","weight":-0.0285},{"period":"6month","weight":-0.1677},{"period":"1year","weight":-0.0044},{"period":"ytd","weight":-0.0133}],"compareEarnings":[{"period":"1week","weight":-0.0093},{"period":"1month","weight":0.0054},{"period":"3month","weight":0.0567},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.2198},{"period":"ytd","weight":0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海复旦张江生物医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21005人(较上一季度增加6.42%)","perCapita":"33828股","listingDate":"2020-06-19","address":"上海市浦东新区张江高科技园区蔡伦路308号","registeredCapital":"10365万元","survey":" 上海复旦张江生物医药股份有限公司的主营业务是生物医药的创新研究开发、生产制造和市场营销。公司的主要产品是皮肤科产品、抗肿瘤产品。","listedPrice":8.95},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复旦张江(688505)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复旦张江(688505)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复旦张江,688505,复旦张江股票,复旦张江股票老虎,复旦张江股票老虎国际,复旦张江行情,复旦张江股票行情,复旦张江股价,复旦张江股市,复旦张江股票价格,复旦张江股票交易,复旦张江股票购买,复旦张江股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复旦张江(688505)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复旦张江(688505)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}